From understanding diseases to drug design: can artificial intelligence bridge the gap?

被引:9
|
作者
Pushkaran, Anju Choorakottayil [1 ]
Arabi, Alya A. [1 ]
机构
[1] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Biochem & Mol Biol, POB 15551, Al Ain, U Arab Emirates
关键词
Artificial intelligence; Machine learning; Disease identification; Drug discovery; TARGET IDENTIFICATION; DIABETIC-RETINOPATHY; NEURAL-NETWORKS; DEEP; CLASSIFICATION; VALIDATION; PREDICTION; ALGORITHM; DISCOVERY; CANCER;
D O I
10.1007/s10462-024-10714-5
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
Artificial intelligence (AI) has emerged as a transformative technology with significant potential to revolutionize disease understanding and drug design in healthcare. AI serves as a remarkable accelerating tool that bridges the gap between understanding diseases and discovering drugs. Given its capacity in the analysis and interpretation of massive amounts of data, AI is tremendously boosting the power of predictions with impressive accuracies. This allowed AI to pave the way for advancing all key stages of drug development, with the advantage of expediting the drug discovery process and curbing its costs. This is a comprehensive review of the recent advances in AI and its applications in drug discovery and development, starting with disease identification and spanning through the various stages involved in the drug discovery pipeline, including target identification, screening, lead discovery, and clinical trials. In addition, this review discusses the challenges that arise during the implementation of AI at each stage of the discovery process and provides insights into the future prospects of this field.
引用
收藏
页数:39
相关论文
共 50 条
  • [21] How artificial Intelligence can detect rare Diseases
    不详
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (02): : 134 - 134
  • [22] How Artificial Intelligence can detect Rare Diseases
    不详
    GYNAKOLOGE, 2019, 52 (10): : 743 - 743
  • [23] How artificial Intelligence can track Rare Diseases
    不详
    KARDIOLOGE, 2019, 13 (04): : 197 - 197
  • [24] Bridging the accountability gap of artificial intelligence - what can be learned from Roman law?
    Heine, Klaus
    Quintavalla, Alberto
    LEGAL STUDIES, 2024, 44 (01) : 65 - 80
  • [25] Rethinking drug design in the artificial intelligence era
    Petra Schneider
    W. Patrick Walters
    Alleyn T. Plowright
    Norman Sieroka
    Jennifer Listgarten
    Robert A. Goodnow
    Jasmin Fisher
    Johanna M. Jansen
    José S. Duca
    Thomas S. Rush
    Matthias Zentgraf
    John Edward Hill
    Elizabeth Krutoholow
    Matthias Kohler
    Jeff Blaney
    Kimito Funatsu
    Chris Luebkemann
    Gisbert Schneider
    Nature Reviews Drug Discovery, 2020, 19 : 353 - 364
  • [26] Rethinking drug design in the artificial intelligence era
    Schneider, Petra
    Walters, W. Patrick
    Plowright, Alleyn T.
    Sieroka, Norman
    Listgarten, Jennifer
    Goodnow, Robert A., Jr.
    Fisher, Jasmin
    Jansen, Johanna M.
    Duca, Jose S.
    Rush, Thomas S.
    Zentgraf, Matthias
    Hill, John Edward
    Krutoholow, Elizabeth
    Kohler, Matthias
    Blaney, Jeff
    Funatsu, Kimito
    Luebkemann, Chris
    Schneider, Gisbert
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (05) : 353 - 364
  • [27] Symbol grounding: A bridge from artificial life to artificial intelligence
    Thompson, E
    BRAIN AND COGNITION, 1997, 34 (01) : 48 - 71
  • [28] Bridge the Gap! What Can Work Design in Crowdwork Learn from Work Design Theories?
    Anya, Obinna
    PROCEEDINGS OF THE 2015 ACM INTERNATIONAL CONFERENCE ON COMPUTER-SUPPORTED COOPERATIVE WORK AND SOCIAL COMPUTING (CSCW'15), 2015, : 612 - 627
  • [29] Big data and benchmarking initiatives to bridge the gap from AlphaFold to drug design
    Schapira, Matthieu
    Halabelian, Levon
    Arrowsmith, Cheryl H.
    Harding, Rachel J.
    NATURE CHEMICAL BIOLOGY, 2024, 20 (08) : 937 - 940
  • [30] Artificial intelligence and Italian culture: an understanding of how artificial intelligence can transform the radiation therapy landscape
    Francesca De Felice
    Medical Oncology, 40